» Articles » PMID: 21199859

Wolfram Syndrome 1 Gene (WFS1) Product Localizes to Secretory Granules and Determines Granule Acidification in Pancreatic Beta-cells

Overview
Journal Hum Mol Genet
Date 2011 Jan 5
PMID 21199859
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Wolfram syndrome is an autosomal recessive disorder characterized by juvenile-onset insulin-dependent diabetes mellitus and optic atrophy. The gene responsible for the syndrome (WFS1) encodes an endoplasmic reticulum (ER) resident transmembrane protein. The Wfs1-null mouse exhibits progressive insulin deficiency causing diabetes. Previous work suggested that the function of the WFS1 protein is connected to unfolded protein response and to intracellular Ca(2+) homeostasis. However, its precise molecular function in pancreatic β-cells remains elusive. In our present study, immunofluorescent and electron-microscopic analyses revealed that WFS1 localizes not only to ER but also to secretory granules in pancreatic β-cells. Intragranular acidification was assessed by measuring intracellular fluorescence intensity raised by the acidotrophic agent, 3-[2,4-dinitroanilino]-3'-amino-N-methyldipropyramine. Compared with wild-type β-cells, there was a 32% reduction in the intensity in WFS1-deficient β-cells, indicating the impairment of granular acidification. This phenotype may, at least partly, account for the evidence that Wfs1-null islets have impaired proinsulin processing, resulting in an increased circulating proinsulin level. Morphometric analysis using electron microscopy evidenced that the density of secretory granules attached to the plasma membrane was significantly reduced in Wfs1-null β-cells relative to that in wild-type β-cells. This may be relevant to the recent finding that granular acidification is required for the priming of secretory granules preceding exocytosis and may partly explain the fact that glucose-induced insulin secretion is profoundly impaired in young prediabetic Wfs1-null mice. These results thus provide new insights into the molecular mechanisms of β-cell dysfunction in patients with Wolfram syndrome.

Citing Articles

Sodium valproate, a potential repurposed treatment for the neurodegeneration in Wolfram syndrome (TREATWOLFRAM): trial protocol for a pivotal multicentre, randomised double-blind controlled trial.

Dias R, Brock K, Hu K, Gupta R, Martin U, Peet A BMJ Open. 2025; 15(2):e091495.

PMID: 40010822 PMC: 11865774. DOI: 10.1136/bmjopen-2024-091495.


Comprehensive overview of disease models for Wolfram syndrome: toward effective treatments.

Morikawa S, Tanabe K, Kaneko N, Hishimura N, Nakamura A Mamm Genome. 2024; 35(1):1-12.

PMID: 38351344 DOI: 10.1007/s00335-023-10028-x.


ISR inhibition reverses pancreatic β-cell failure in Wolfram syndrome models.

Hu R, Chen X, Su Q, Wang Z, Wang X, Gong M Cell Death Differ. 2024; 31(3):322-334.

PMID: 38321214 PMC: 10923889. DOI: 10.1038/s41418-024-01258-w.


Selective proteasome degradation of C-terminally-truncated human WFS1 in pancreatic beta cells.

Tokuma H, Sakano D, Tanabe K, Tanizawa Y, Shiraki N, Kume S FEBS Open Bio. 2023; 13(8):1405-1414.

PMID: 37440664 PMC: 10392043. DOI: 10.1002/2211-5463.13674.


The genetic and clinical characteristics of WFS1 related diabetes in Chinese early onset type 2 diabetes.

Li Y, Gong S, Li M, Cai X, Liu W, Zhang S Sci Rep. 2023; 13(1):9127.

PMID: 37277527 PMC: 10241780. DOI: 10.1038/s41598-023-36334-7.